This study from 2017 - 2019 compares the outcomes for oncology and non-oncology appraisals conducted...
Read moreIn England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...
Read moreA targeted drug has been accepted for routine use on the NHS in England for some adults with untreat...
Read moreBy joining together, countries can combine their resources to potentially increase the efficiency of...
Read morePharmaceutical pricing and market access is the crucial challenge for successful product launch toda...
Read moreWhat is the future of precision medicine in the EU? The field of precision medicine is a complex are...
Read moreNICE will continue to offer joint advice with the Medicines and Healthcare products Regulatory Agenc...
Read moreThe law provides a legal framework for the automatic substitution of biosimilars at the level of the...
Read moreNICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...
Read moreSpeaking at the international pharma conference, NICE’s chief executive Sir Andrew Dillon struck a...
Read more